This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -35.14% and -28.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Denali Therapeutics Inc. (DNLI) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 7th
by Zacks Equity Research
ACCD, DNLI, FSLY, FHB and GH have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2021.
Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal
by Zacks Equity Research
Biogen's (BIIB) rare, inherited retinal disease gene therapy candidate, timrepigene emparvovec, fails to meet the primary endpoint in a phase III study.
Denali Therapeutics (DNLI) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Denali Therapeutics (DNLI) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Why Is Denali Therapeutics Inc. (DNLI) Up 10.7% Since Last Earnings Report?
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen (BIIB) Eye Disease Drug Misses Primary Goal in Study
by Zacks Equity Research
Biogen's (BIIB) rare, inherited retinal disease candidate, cotoretigene toliparvovec fails to meet the primary endpoint in a phase II/III study.
Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate
by Zacks Equity Research
Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)
Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders
by Zacks Equity Research
Biogen (BIIB) and Capsigen set to collaborate to make AAV capsids that have the potential to deliver transformative gene therapies for various CNS and neuromuscular disorders.
Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Denali (DNLI) posts a wider-than-expected loss in the first quarter of 2021 due to higher R&D costs.
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -56.76% and -72.76%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Denali Therapeutics Inc. (DNLI) Down 12.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal
by Zacks Equity Research
Denali (DNLI) posts earnings in the fourth quarter of 2020 due to collaboration revenues from Biogen.
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Medical Outperformers That Might Lose Steam in 2021
by Zacks Equity Research
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
Denali Therapeutics (DNLI) Surges: Stock Moves 5.7% Higher
by Zacks Equity Research
Denali Therapeutics (DNLI) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 8.20% and 57.60%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Denali Therapeutics Inc. (DNLI) a New Buy Stock
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Denali Therapeutics Inc (DNLI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc (DNLI) delivered earnings and revenue surprises of 3.51% and -39.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.
Zoetis' (ZTS) Q1 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Zoetis (ZTS) beats on earnings in the first quarter of 2020 while sales meet estimates. Domestic revenues bumped up owing to growth in new parasiticide products and a robust dermatology portfolio.
Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -5.66% and -70.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?